Cover Image
市場調查報告書

藥物輸送及基因轉移設備市場分析:藥物輸送類別(口服,吸入,經皮,注射,眼球,鼻子,局部),各媒介(病毒,非病毒),基因轉移類別,及市場區隔預測

Drug And Gene Delivery Devices Market Analysis By Drug Delivery Type (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical), By Gene Delivery Vector (Viral, Non-viral), By Gene Delivery Type, And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 421168
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物輸送及基因轉移設備市場分析:藥物輸送類別(口服,吸入,經皮,注射,眼球,鼻子,局部),各媒介(病毒,非病毒),基因轉移類別,及市場區隔預測 Drug And Gene Delivery Devices Market Analysis By Drug Delivery Type (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical), By Gene Delivery Vector (Viral, Non-viral), By Gene Delivery Type, And Segment Forecasts, 2014 - 2025
出版日期: 2016年12月08日 內容資訊: 英文 90 Pages
簡介

本報告提供全球藥物輸送及基因轉移設備市場相關調查,彙整市場趨勢,各類型,各媒介,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 調查方法與範圍

第2章 摘要整理

第3章 市場變動,趨勢,範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
    • 阻礙市場的要素分析
  • 滲透·成長預測製圖
  • SWOT分析
  • 產業分析:波特五力分析

第4章 各給藥途徑預測·趨勢分析

  • 藥物遞輸系統市場:各給藥途徑趨勢分析
  • 口服
  • 吸入
  • 經皮
  • 眼球
  • 鼻子
  • 局部

第5章 各基因轉移系統:媒介預測·趨勢分析

  • 各媒介趨勢分析與市場佔有率
  • 病毒載體
  • 非病毒載體

第6章 基因轉移系統:各手法預測·趨勢分析

  • 各手法趨勢分析
  • Ex vivo
  • In situ

第7章 各地區預測·趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第8章 競爭環境

  • 策略架構
  • 市場進入分類
  • 企業簡介
目錄
Product Code: GVR-1-68038-238-9

The global drug and gene delivery systems market is expected to reach USD 786.9 Billion by 2025, according to a new report by Grand View Research, Inc. Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future.

Drug delivery systems are in a constant evolution along with the changing preference by the patient. For instance, initially, hormone replacement therapy was widely prescribed in the form of pills, whereas, it is now available in the form of prefilled syringes, patches, vaginal rings, gel, and sprays. The principal purpose of development of different forms of delivery systems is to increase the ease of use. Factors such as aesthetics of the delivery systems, price, and amount of API are also considered while designing the drug delivery system.

Further key findings from the study suggest:

  • The market study suggests that oral segment dominated the market in 2015
  • The convenience of use and low manufacturing cost are the prime factors responsible for the dominance of the oral delivery segment
  • Injectable segment is expected to show a lucrative growth rate owing to the introduction of technically advanced injecting devices that enable convenient self-injection
  • North America dominated the market in 2015 and is expected to remain dominant throughout the forecast period owing to highly developed healthcare infrastructure and high healthcare spending
  • Asia pacific is expected to exhibit the fastest growth rate during the forecast period owing to the factors such as rapidly developing economies, growing disposable income, and high adaption of the advanced delivery systems
  • A few of the major market players in drug delivery systems space are F. Hoffmann-La Roche Ltd, Pfizer, Inc., Johnson and Johnson private Ltd, Novartis AG, Becton, Dickinson and Company, and Bayer AG.
  • Major market players in the gene delivery systems space are SiBiono GeneTech Co., Unique N.V., Epeius Biotechnologies Corporation, Human Stem Cells Institute, and Shanghai Sunway Biotech Co., Ltd.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information procurement
  • 1.2 Data Analysis
  • 1.3 Approaches for market estimation
    • 1.3.1 Approach 1: Demand Analysis & Bottom up Approach
    • 1.3.2 Approach 2: Top down market estimation
    • 1.3.3 Approach 3: Commodity flow and bottom up market estimation
    • 1.3.4 Approach 4: KoL perspective based market sizing

Chapter 2 Executive Summary

  • 2.1 Market snapshot

Chapter 3 Drug and Gene Delivery Systems Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Driver Analysis
    • 3.1.2 Market Restraint Analysis
  • 3.2 Penetration & growth prospect mapping
  • 3.3 Drug and Gene Delivery Systems - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Drug Delivery Systems Market: Route of Administration Estimates & Trend Analysis

  • 4.1 Drug delivery systems market: Route of Administration Movement Analysis
  • 4.2 Oral
    • 4.2.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 4.3 Inhalation
    • 4.3.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 4.4 Transdermal
    • 4.4.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 4.5 Injectable
    • 4.5.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 4.6 Ocular
    • 4.6.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 4.7 Nasal
    • 4.7.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 4.8 Topical
    • 4.8.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)

Chapter 5 Gene Delivery Systems: Vector Estimates & Trend Analysis

  • 5.1 Gene Delivery Systems Market: Vector Movement Analysis
  • 5.2 Viral Vectors
    • 5.2.1 Market Estimates and Forecast, 2014 - 2025 (USD Million)
  • 5.3 Non-viral Vectors
    • 5.3.1 Market Estimates and Forecast, 2014 - 2025 (USD Million)

Chapter 6 Gene Delivery Systems: Method Estimates & Trend Analysis

  • 6.1 Gene delivery Systems Market: Method Movement Analysis
  • 6.2 Ex vivo
    • 6.3.1 Market Estimates and Forecast, 2014 - 2025 (USD Million)
  • 6.4 In situ
    • 6.4.1 Market Estimates and Forecast, 2014 - 2025 (USD Million)

Chapter 7 Drug and Gene Delivery Systems: Regional Estimates & Trend Analysis, by Route of Administration, Vector and Method

  • 7.1 Drug and gene delivery systems market share by region, 2014 & 2025
  • 7.2 North America
    • 7.2.1 U.S.
      • 7.2.1.1 Market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
      • 7.2.1.2 Market estimates and forecasts, by vector 2014 - 2025, USD Million
      • 7.2.1.3 Market estimates and forecasts, by method 2014 - 2025, USD Million
    • 7.2.2 Canada
      • 7.2.2.1 Market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
      • 7.2.2.2 Market estimates and forecasts, by vector 2014 - 2025, USD Million
      • 7.2.2.3 Market estimates and forecasts, by method 2014 - 2025, USD Million
  • 7.3 Europe
    • 7.3.1 U.K.
      • 7.3.1.1 Market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
      • 7.3.1.2 Market estimates and forecasts, by vector 2014 - 2025, USD Million
      • 7.3.1.3 Market estimates and forecasts, by method 2014 - 2025, USD Million
    • 7.3.2 Germany
      • 7.3.2.1 Market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
      • 7.3.2.2 Market estimates and forecasts, by vector 2014 - 2025, USD Million
      • 7.3.2.3 Market estimates and forecasts, by method 2014 - 2025, USD Million
  • 7.4 Asia Pacific
    • 7.4.1 Japan
      • 7.4.1.1 Market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
      • 7.4.1.2 Market estimates and forecasts, by vector 2014 - 2025, USD Million
      • 7.4.1.3 Market estimates and forecasts, by method 2014 - 2025, USD Million
    • 7.4.2 China
      • 7.4.2.1 Market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
      • 7.4.2.2 Market estimates and forecasts, by vector 2014 - 2025, USD Million
      • 7.4.2.3 Market estimates and forecasts, by method 2014 - 2025, USD Million
  • 7.5 Latin America
    • 7.5.1 Brazil
      • 7.5.1.1 Market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
      • 7.5.1.2 Market estimates and forecasts, by vector 2014 - 2025, USD Million
      • 7.5.1.3 Market estimates and forecasts, by method 2014 - 2025, USD Million
    • 7.5.2 Mexico
      • 7.5.2.1 Market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
      • 7.5.2.2 Market estimates and forecasts, by vector 2014 - 2025, USD Million
      • 7.5.2.3 Market estimates and forecasts, by method 2014 - 2025, USD Million
      • 7.5.2.4 Market estimates and forecasts, by method 2014 - 2025
  • 7.6 Middle East and Africa (MEA)
    • 7.6.1 South Africa
      • 7.6.1.1 Market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
      • 7.6.1.2 Market estimates and forecasts, by vector 2014 - 2025, USD Million
      • 7.6.1.3 Market estimates and forecasts, by method 2014 - 2025, USD Million

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Market Participation Categorization
  • 8.3 Company Profiles
    • 8.3.1 Pfizer, Inc.
      • 8.3.1.1 Company Overview
      • 8.3.1.2 Financial Performance
      • 8.3.1.3 Product Benchmarking
      • 8.3.1.4 Strategic Initiatives
    • 8.3.2 F. Hoffmann-La Roche Ltd.
      • 8.3.2.1 Company Overview
      • 8.3.2.2 Financial Performance
      • 8.3.2.3 Product Benchmarking
      • 8.3.2.4 Strategic Initiatives
    • 8.3.3 Johnson and Johnson
      • 8.3.3.1 Company Overview
      • 8.3.3.2 Financial Performance
      • 8.3.3.3 Product Benchmarking
      • 8.3.3.4 Strategic Initiatives
    • 8.3.4 Novartis AG
      • 8.3.4.1 Company Overview
      • 8.3.4.2 Financial Performance
      • 8.3.4.3 Product Benchmarking
      • 8.3.4.4 Strategic Initiatives
    • 8.3.5 Bayer AG
      • 8.3.5.1 Company Overview
      • 8.3.5.2 Financial Performance
      • 8.3.5.3 Product Benchmarking
      • 8.3.5.4 Strategic Initiatives
    • 8.3.6 Becton, Dickinson and Company
      • 8.3.6.1 Company Overview
      • 8.3.6.2 Financial Performance
      • 8.3.6.3 Product Benchmarking
      • 8.3.6.4 Strategic Initiatives
    • 8.3.7 Uniqure N.V
      • 8.3.7.1 Company Overview
      • 8.3.7.2 Financial Performance
      • 8.3.7.3 Product Benchmarking
      • 8.3.7.4 Strategic Initiatives
    • 8.3.8 SiBiono GeneTech Co
      • 8.3.8.1 Company Overview
      • 8.3.8.2 Financial Performance
      • 8.3.8.3 Product Benchmarking
      • 8.3.8.4 Strategic Initiatives
    • 8.3.9 Shanghai Sunway Biotech Co., Ltd
      • 8.3.9.1 Company Overview
      • 8.3.9.2 Product Benchmarking
      • 8.3.9.3 Strategic Initiatives
    • 8.3.10 Human Stem Cells Institute
      • 8.3.10.1 Company Overview
      • 8.3.10.2 Financial Performance
      • 8.3.10.3 Product Benchmarking
      • 8.3.10.4 Strategic Initiatives

List of Tables

  • TABLE 1 North America Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 2 North America Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 3 North America Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 4 U.S. Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 5 U.S. Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 6 U.S. Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 7 Canada Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 8 Canada Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 9 Canada Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 10 Europe Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 11 Europe Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 12 Europe Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 13 U.K. Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 14 U.K. Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 15 U.K. Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 16 Germany Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 17 Germany Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 18 Germany Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 19 Asia Pacific Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 20 Asia Pacific Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 21 Asia Pacific Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 22 Japan Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 23 Japan Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 24 Japan Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 25 China Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 26 China Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 27 China Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 28 Latin America Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 29 Latin America Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 30 Latin America Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 31 Brazil Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 32 Brazil Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 33 Brazil Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 34 Mexico Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 35 Mexico Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 36 Mexico Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 37 MEA Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 38 MEA Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 39 MEA Gene Delivery Market, by Method, 2014 - 2025 (USD Million)
  • TABLE 40 South Africa Drug Delivery Systems Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • TABLE 41 South Africa Gene Delivery Market, by Vector, 2014 - 2025 (USD Million)
  • TABLE 42 South Africa Gene Delivery Market, by Method, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary (USD Billion)
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 Penetration & growth prospect mapping
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Drug delivery systems market route of administration outlook key takeaways
  • FIG. 16 Drug delivery systems: Type Movement Analysis
  • FIG. 17 Oral Market, 2014 - 2025 (USD Billion)
  • FIG. 18 Inhalation Market, 2014 - 2025 (USD Billion)
  • FIG. 19 Transdermal Market, 2014 - 2025 (USD Billion)
  • FIG. 20 Injectable Market, 2014 - 2025 (USD Billion)
  • FIG. 21 Ocular Market, 2014 - 2025 (USD Billion)
  • FIG. 22 Nasal Market, 2014 - 2025 (USD Billion)
  • FIG. 23 Topical Market, 2014 - 2025 (USD Billion)
  • FIG. 24 Gene delivery systems market material outlook key takeaways
  • FIG. 25 Gene Delivery Systems: Material Movement Analysis
  • FIG. 26 Viral Vectors Market, 2014 - 2025 (USD Million)
  • FIG. 27 Non-viral Vectors Market, 2014 - 2025 (USD Million)
  • FIG. 28 Gene delivery systems market method outlook key takeaways
  • FIG. 29 Gene Delivery Systems: Method Movement Analysis
  • FIG. 30 Ex vivo Market, 2014 - 2025 (USD Million)
  • FIG. 31 In situ Market, 2014 - 2025 (USD Million)
  • FIG. 32 Regional market place: Key takeaways
  • FIG. 33 Regional outlook, 2014 & 2024
  • FIG. 34 Strategy framework
  • FIG. 35 Participant categorization
Back to Top